Liposome Patents (Class 977/907)
-
Patent number: 8252324Abstract: A targeted drug delivery nanocarrier and a method of forming the same is disclosed herein. The targeted drug delivery nanocarrier includes a plurality of amphipathic molecules forming a carrier particle having a plurality of drug molecules contained therein. A targeted landscape phage protein assembly is complexed to the carrier particle preferably using the unique method disclosed herein. The targeted landscape phage protein assembly displays a binding peptide that is selected to specifically and selectively bind to a target site. The method for forming targeted drug delivery nanocarriers includes the steps of obtaining a plurality of bacteriophage displaying a binding peptide for a desired target site, treating the bacteriophage with a denaturing agent, mixing the treated bacteriophage with a plurality of carrier particles and purifying the mixture to obtain a plurality of targeted drug delivery nanocarriers.Type: GrantFiled: February 8, 2012Date of Patent: August 28, 2012Assignee: Auburn UniversityInventor: Valery A. Petrenko
-
Patent number: 8241663Abstract: A liposome preparation is provided. This liposome preparation is capable of stably encapsulating a drug which is unstable under an acidic condition, and such stable encapsulation is realized without detracting the effect realized by the modification of the membrane by a hydrophilic macromolecule such as stability in blood. More specifically, the liposome preparation comprises a unilamellar vesicle formed from a lipid bilayer comprising a phospholipid as its main membrane component, and an interior aqueous phase of the vesicle at a pH of up to 5. The liposome has a drug loaded therein, and the vesicle is modified with a hydrophilic macromolecule only on its exterior surface.Type: GrantFiled: March 25, 2005Date of Patent: August 14, 2012Assignee: Terumo Kabushiki KaishaInventors: Masashi Isozaki, Keisuke Yoshino, Kyoko Taguchi, Masayo Kondo
-
Publication number: 20120201872Abstract: Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.Type: ApplicationFiled: August 3, 2010Publication date: August 9, 2012Applicant: The University of North Carolina at Chapel HillInventors: Leaf Huang, Jun Li
-
Patent number: 8236770Abstract: The invention relates to amphoteric liposomal formulations which are provided with great serum stability and are suitable for the intracellular delivery of oligonucleotides.Type: GrantFiled: March 29, 2005Date of Patent: August 7, 2012Assignee: Marina Biotech, Inc.Inventors: Gerold Endert, Yvonne Kerwitz, Monika Fellermeier
-
Publication number: 20120195948Abstract: The present invention relates to the use of dedifferentiated plant cells in cosmetic preparations for protecting of stem cells against intrinsic and extrinsic stress factors, in particular for promoting proliferation of stem cells and for protecting them against apoptosis. In particular, the invention relates to the use of dedifferentiated plant cells from fruits of Malus domestica (Apple) cultivar Uttwiler Spaetlauber. Further, the invention relates to a method for cultivating of dedifferentiated plant cells, as well as to the preparation of extracts of plant cell cultures which are suitable for such applications.Type: ApplicationFiled: April 11, 2012Publication date: August 2, 2012Applicant: Mibelle AGInventors: Peter Blum, Cornelia Schürch, Daniel Schmid, Fred Zülli
-
Publication number: 20120195957Abstract: Methods and formulations for treating a condition of the skin by delivering therapeutic formulations to the skin that translocates active substances across the stratum corneum barrier to a targeted skin tissue. The methods and formulations comprise active substances encapsulated within surface modified nanostructured lipid carrier nanoparticles.Type: ApplicationFiled: April 30, 2009Publication date: August 2, 2012Inventors: Mandip Singh Sachdeva, Ram Patlolla
-
Publication number: 20120189677Abstract: A formulation comprising botulinum toxin (BT), lipid and surfactant, characterised in that the lipid and surfactant are in the form of macromolecular assemblies of less than 100 nm in diameter. The surfactant may have an HLB number of less than 20.Type: ApplicationFiled: January 20, 2012Publication date: July 26, 2012Inventors: Stephen TONGE, Andrew HARPER
-
Publication number: 20120189688Abstract: The present invention provides a carrier component. The carrier component includes a carrier core body including a dispersive object and a dualistic self-assembly material for encapsulating the dispersive object, wherein the dualistic self-assembly material has an electric charge; and a first shell layer having an electric charge opposite to the electric charge of the dualistic self-assembly material, and coating the carrier core body, and thus avoids inactivation of a medicine, eliminates medicine leakage and reduces medicine releasing. The present invention further provides a method for forming a carrier component.Type: ApplicationFiled: May 20, 2011Publication date: July 26, 2012Applicant: NATIONAL CHIAO TUNG UNIVERSITYInventors: Dean-Mo Liu, Chun Yu Chang, Fu Hsuan Chou, Tin-Yo Yen
-
Patent number: 8211948Abstract: The present invention relates to a lyophilized nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilized nanoemulsion by redispersion, and to a process for the preparation of the lyophilized nanoemulsion.Type: GrantFiled: February 26, 2009Date of Patent: July 3, 2012Assignee: Merck Patent GmbHInventors: Andrea Hanefeld, Martina Schmidt, Simon Geissler, Peter Langguth
-
Publication number: 20120164065Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: January 11, 2012Publication date: June 28, 2012Inventors: Anthony Manganaro, Karen Rockwell
-
Publication number: 20120164214Abstract: Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these lipospmes.Type: ApplicationFiled: August 26, 2010Publication date: June 28, 2012Applicant: Technion Research & Development Foundation Ltd.Inventors: Marcelle Machluf, Tomer Bronshtein
-
Publication number: 20120164072Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.Type: ApplicationFiled: May 4, 2010Publication date: June 28, 2012Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman
-
Publication number: 20120121689Abstract: A liposomal siRNA composition is described. The liposomes are formed of neutral liposome forming components, and the composition comprising additionally sugar. The composition provides reduced expression of target gene, without causing systemic toxicity. The composition is produced by a dehydration-rehydration technique to provide high yields and good control of liposome size.Type: ApplicationFiled: November 9, 2009Publication date: May 17, 2012Applicant: Lipoxen Technologies LimitedInventors: Andrew David Bacon, Peter Laing, Gregory Gregoriadis
-
Publication number: 20120100207Abstract: [Problem] To provide a process for producing liposomes, a liposome dispersion or a dry powder of the dispersion by a two-step emulsification method using an additive (dispersing agent) by which a liposome dispersion and a dry powder thereof which can inhibit leakage of an encapsulated drug or the like from liposomes even in the long-term storage and can be stably used over a long period of time are obtained. [Solution to problem] A process for producing liposomes by a two-step emulsification method characterized by using, in the secondary emulsification step, an outer aqueous phase containing a dispersing agent which forms no molecular self-aggregate or a dispersing agent which exclusively forms molecular self-aggregates having a volume mean particle diameter of not more than 10 nm (said dispersing agent being referred to as a “specific dispersing agent” hereinafter), and a process for producing a liposome dispersion or a dry powder thereof utilizing the process for producing liposomes.Type: ApplicationFiled: June 2, 2010Publication date: April 26, 2012Applicant: KONICA MINOLTA HOLDINGS, INC.Inventors: Yasuyuki Motokui, Takeshi Wada, Takeshi Isoda
-
Publication number: 20120093916Abstract: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject.Type: ApplicationFiled: September 23, 2011Publication date: April 19, 2012Inventor: William F. Kaemmerer
-
Publication number: 20120087974Abstract: The present invention provides compositions comprising allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages. In some embodiments a positive charge and enhancers are used in the compositions to allow for increased penetration of the active ingredient through skin and skin appendages. In some embodiments the positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The present invention also provides methods for making compositions comprising an allylamine drug compound, and methods of using such compositions for the treatment of fungal infections of the skin and skin appendages.Type: ApplicationFiled: October 4, 2011Publication date: April 12, 2012Inventors: Pichit Suvanprakorn, Panida Vayumhasuwan, Nardo Zaias
-
Publication number: 20120082616Abstract: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Mallinckrodt LLCInventors: Bobby N. Trawick, Todd A. Osiek, James R. Wheatley, JR.
-
Patent number: 8137693Abstract: A targeted drug delivery nanocarrier and a method of forming the same is disclosed herein. The targeted drug delivery nanocarrier includes a plurality of amphipathic molecules forming a carrier particle having a plurality of drug molecules contained therein. A targeted landscape phage protein assembly is complexed to the carrier particle preferably using the unique method disclosed herein. The targeted landscape phage protein assembly displays a binding peptide that is selected to specifically and selectively bind to a target site. The method for forming targeted drug delivery nanocarriers includes the steps of obtaining a plurality of bacteriophage displaying a binding peptide for a desired target site, treating the bacteriophage with a denaturing agent, mixing the treated bacteriophage with a plurality of carrier particles and purifying the mixture to obtain a plurality of targeted drug delivery nanocarriers.Type: GrantFiled: September 29, 2006Date of Patent: March 20, 2012Assignee: Auburn UniversityInventor: Valery A. Petrenko
-
Publication number: 20120058177Abstract: The present invention provides an aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises (a) a legumain-targeting lipid component, (b) a zwitterionic lipid component; (c) an amino-substituted lipid component; (d) a neutral lipid component; and (e) polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalenetly attached to a legumain-binding moiety.Type: ApplicationFiled: September 2, 2011Publication date: March 8, 2012Inventors: Ralph A. Reisfeld, Rong Xiang, Yunping Luo, Debbie Liao, Ze Liu, Tingmei Chen, Si Chen, Dan Lu
-
Publication number: 20120052114Abstract: Embodiments of the present invention are directed to an apparatus and methods for making nucleic acid loaded nanosomes. One embodiment of the present invention directed to an apparatus comprises a first containment means for containing a mixture of an aqueous solution of nucleic acid and a phospholipid solution with a supercritical, critical or near critical fluid. The apparatus further comprises injection means in fluid communication with said first containment means for receiving the mixture and releasing the mixture as a stream into a decompression liquid. The apparatus further comprises a decompression vessel in fluid communication with the injection means for holding a decompression liquid and receiving the mixture as a stream. The stream forms one or more nanosomes loaded with a nucleic acid in the decompression liquid.Type: ApplicationFiled: August 23, 2011Publication date: March 1, 2012Inventor: Trevor Percival CASTOR
-
Publication number: 20120052115Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.Type: ApplicationFiled: April 21, 2010Publication date: March 1, 2012Applicants: Emory University, Georgia Tech Research CorporationInventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
-
Publication number: 20120040007Abstract: The method for preventing and delaying inherited retinal degenerations using serine palmitoyltransferase inhibitors, and compositions which contain them.Type: ApplicationFiled: February 23, 2010Publication date: February 16, 2012Applicants: UNIVERSITA' DEGLI STUDI DI MILANO, NANOVECTOR S.R.L., UNIVERSITA' DEGLI STUDI DL PISA, CONSIGLIO NAZIONALE DELLE RICERCHEInventors: Riccardo Ghidoni, Enrica Strettoi, Maria Claudia Gargini, Paolo Gasco
-
Publication number: 20120034294Abstract: Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm.Type: ApplicationFiled: December 17, 2009Publication date: February 9, 2012Applicant: ONCOTHYREON, INC.Inventors: Robert A. Dupuit, William J. Reilley
-
Publication number: 20120009252Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.Type: ApplicationFiled: September 20, 2011Publication date: January 12, 2012Applicant: CELATOR PHARMACEUTICALS, INC.Inventors: Lawrence MAYER, Sharon Johnstone, Troy Harasym
-
Publication number: 20110311442Abstract: A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a fusion protein is provided. The vesicle can further comprise a biomolecule, such as for example ATP. Methods of using the vesicle for delivery of biomolecules are also provided.Type: ApplicationFiled: June 17, 2011Publication date: December 22, 2011Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: William D. Ehringer, Sufan Chien
-
Publication number: 20110311616Abstract: Provided herein are compositions including particles that comprise a bisphosphonate compound and a tumor specific targeting peptide or peptidomimetic. Also provided herein are methods of reducing tumor associated macrophages and methods of treating cancer with said compositions.Type: ApplicationFiled: June 16, 2011Publication date: December 22, 2011Inventors: Jeff Smith, Gaurav Sharma
-
Publication number: 20110287075Abstract: The invention features a galvanic particulate including a first conductive material and a second conductive material, wherein both the first conductive material and the second conductive material are exposed on the surface of the particulate, wherein the particle size of the particulate is from about 10 nanometers to about 100 micrometers, wherein the second conductive material comprises from about 0.01 percent to about 10 percent, by weight, of the total weight of the particulate, and wherein the difference of the standard potentials of the first conductive material and the second conductive material is at least about 0.2 V.Type: ApplicationFiled: August 5, 2011Publication date: November 24, 2011Inventors: Jeannette Chantalat, James E. Hauschild, Jue-Chen Liu, Xintian Ming, Michael Southhall, Ying Sun
-
Publication number: 20110280933Abstract: Provided herein are methods and compositions for treating a subject who has pulmonary damage or an injury caused by or who is at risk for an injury caused by an anti-vesicant agent. The compositions comprise cacao extracts that include a mixture of epicatechin and one or more epicatechin oligomers and a pharmaceutically acceptable carrier. Also provided are methods for fermenting cacao to enhance epicatechin and antioxidant content.Type: ApplicationFiled: March 24, 2011Publication date: November 17, 2011Applicant: CACAO BIO-TECHNOLOGIES, LLCInventors: Daniel PRESTON, Randall B. Murphy
-
Publication number: 20110268791Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.Type: ApplicationFiled: January 5, 2010Publication date: November 3, 2011Inventors: Juewen Liu, Jeffrey C. Brinker, Carlee Ashley
-
Publication number: 20110268659Abstract: In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (1) subjecting a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug in nano-size. In an embodiment, a method comprises (1) subjecting a drug carrier and a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug carrier loaded with the drug. In an embodiment, a method comprises (1) applying high shear to a drug carrier and a therapeutic fluid containing a drug; (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug-loaded carrier; and (3) modifying the drug-loaded carrier with a targeting moiety to obtain a modified drug-loaded carrier.Type: ApplicationFiled: April 8, 2011Publication date: November 3, 2011Applicant: H R D CorporationInventors: Abbas HASSAN, Rayford G. ANTHONY, Aziz HASSAN
-
Publication number: 20110244024Abstract: The invention provides methods, uses, kits and compositions comprising a therapeutically effective amount of the microRNA miR-223 for treating myelogenous leukemia in a subject in need of such treatment. The invention further comprises methods encompassing the use of miR-223 for promoting the differentiation of a leukemia stem cell that is resistant to a differentiating agent, and a method of screening for candidate compounds capable of treating a myeloid leukemia by comparison of the therapeutic activity of the candidate compound with the therapeutic activity of miR-233.Type: ApplicationFiled: August 11, 2008Publication date: October 6, 2011Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Florian Kuchenbauer, Michael Heuser, Richard Keith Humphries
-
Publication number: 20110229556Abstract: The invention provides delivery systems comprised of lipid coated polymer core particles, as well as compositions, methods of synthesis, and methods of use thereof. The particles can be used to carry antigen and adjuvant, resulting in enhanced immune responses.Type: ApplicationFiled: March 21, 2011Publication date: September 22, 2011Applicant: Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Anna Bershteyn, Jaehyun Moon
-
Patent number: 8017147Abstract: A synergistic mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. Numerous ratios may be formulated for aroma, color, flavor, flow (viscosity), taste and uniformity. Moreover, ingredients for sugar substitutes, natural preservatives, nano-dispersion, nano-emulsion, nano-encapsulation of ingredients and apparatus for personalized nutrition are also described herein.Type: GrantFiled: October 2, 2009Date of Patent: September 13, 2011Inventors: Mohammad A. Mazed, Sayeeda Mazed
-
Publication number: 20110213193Abstract: Liposomes comprising magnetic nanoparticles bound to one or more therapeutic agents are disclosed herein. Also disclosed are methods of delivering a therapeutic agent to a patient across the blood brain barrier using these liposomes, and optionally applying an external magnetic field.Type: ApplicationFiled: August 28, 2009Publication date: September 1, 2011Applicant: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Madhavan P.N. Nair, Zainulabedin M. Saiyed
-
Publication number: 20110200666Abstract: To provide a UV protection agent for topical application to the skin or hair with a very high UV filter substance concentration and good adhesion to skin and hair in accordance with the invention there is proposed a UV protection agent having at least one UV filter substrate encapsulated in a vesicle carrier system, wherein the UV protection agent is characterised in that the at least one UV filter substance encapsulated in the vesicular carrier system is soluble in oil and the vesicular carrier system comprises vesicles which are made up of hydrophobised polysaccharides and are of a particle size of between 10 and 1000 nm and have a positive surface charge with a zeta potential in the range of between 1 and 150 mV. In addition there is proposed the use of such a UV protection agent in suitable cosmetic and/or pharmaceutical formulations.Type: ApplicationFiled: July 9, 2010Publication date: August 18, 2011Applicant: ROVI Cosmetics International GmbHInventors: Dirk Teichmüller, Monika Beyer, Michael Sacher
-
Publication number: 20110177009Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.Type: ApplicationFiled: September 3, 2009Publication date: July 21, 2011Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Sander Langereis, Jochen Keupp, Holger Gruell, Dirk Burdinski, Danielle Beelen
-
Patent number: 7976743Abstract: The present invention provides gas-containing liposomes. In particular, the present invention provide methods of generating gas-containing liposomes where the gas is introduced under pressure, as well as gas-containing liposomes which contain a large volume of gas (e.g., 10 ul of gas per 5 mg of gas-containing liposomes). In certain embodiments, the gas-containing liposomes contain nitric oxide gas. In some embodiments, such nitric oxide containing liposomes are used to treat a medical condition that is treatable by nitric oxide gas (e.g., intimal hyperplasia).Type: GrantFiled: October 16, 2007Date of Patent: July 12, 2011Assignees: Northwestern University, Board of Regents, The University of Texas SystemInventors: Shaoling Huang, Patrick Kee, Robert C. MacDonald, David McPherson
-
Publication number: 20110165068Abstract: This invention relates to a liposome medicament, and, more particularly, a liposome medicament with targeting function. The liposome medicament includes a medicament that is encapsulated in a liposome, and the medicament contains an effector molecule or an effector molecule that is combined with a first ligand, and a second ligand that is connected onto the surface of the liposome. The first ligand and/or the second ligand can specifically bind to target tissues or target cells to be treated. Preferably, the first ligand and/or the second ligands are antibodies, such as monoclonal antibodies. This invention also relates to a method of preparation of the liposome medicament and use of the medicament for treatment of diseases especially tumors. This invention further relates to a pharmaceutical composition of the liposome medicament and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 2, 2010Publication date: July 7, 2011Inventors: Yanfang Liu, Jia Liu
-
Publication number: 20110165225Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.Type: ApplicationFiled: May 26, 2009Publication date: July 7, 2011Inventors: Peter Cullis, Marcel Bally
-
Publication number: 20110135713Abstract: The present invention provides protonated compounds having antiviral and antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi. The invention also provides antiviral compositions comprising compounds of the invention. Viruses that may be treated by compositions of the invention include, but are not limited to, HIV, HSV, CMV, HBV, HCV and influenza virus.Type: ApplicationFiled: January 6, 2011Publication date: June 9, 2011Applicant: Lakewood-Amedex, Inc.Inventor: Roderic M.K. Dale
-
Patent number: 7955618Abstract: A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, including up to 20 mole percent of an amphipathic vesicle-forming lipid derivatized with polyethyleneglycol, and optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.Type: GrantFiled: June 5, 2003Date of Patent: June 7, 2011Assignee: Enceladus Pharmaceuticals B.V.Inventors: Josbert Maarten Metselaar, Marca Henriette M. Wauben, Gerrit Storm
-
Publication number: 20110117183Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.Type: ApplicationFiled: October 27, 2010Publication date: May 19, 2011Applicant: GRADALIS, INC.Inventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
-
Publication number: 20110104258Abstract: Provided herein is a composition, a method, and a system for delivering a functional molecule to the cytosol of a cell, comprising a liposome configured to be taken into a cell, including by a process selected from the group consisting of endocytosis, pinocytosis or phagocytosis, the liposome comprising a phase transforming liquid with vapor pressure capable of forming a gas at low pressure, said liquid being associated with the liposome, and the liposome further comprising at least one functional molecule selected from the group consisting of a therapeutic molecule, a detectable label, and a targeting molecule.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Applicant: Brigham Young UniversityInventors: William G. Pit, Ghaleb Husseini
-
Publication number: 20110097387Abstract: The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity.Type: ApplicationFiled: December 7, 2008Publication date: April 28, 2011Inventors: Yechezkel Barenholz, Janos Szebeni, Miklos Toth, Laszlo Rosivall
-
Publication number: 20110070293Abstract: Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.Type: ApplicationFiled: September 23, 2010Publication date: March 24, 2011Inventors: Indu Javeri, Kaliappanadar Nellaiappan
-
Publication number: 20110070292Abstract: Provided herein are methods for preparing liposomes and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparation contains one or more active agents. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.Type: ApplicationFiled: September 23, 2010Publication date: March 24, 2011Inventors: Indu Javeri, Kaliappanadar Nellaiappan, Bharat Dixit
-
Publication number: 20110064794Abstract: A protein-phospholipid dispersion preparation in a drug delivery system is provided, in which the weight ratio of protein to phospholipid is 1:300-300:1 and the particle size is between 5 nm and 1000 nm. The preparation process of the said preparation contains the mixture of protein phase and phospholipid phase and the homogenization process. The said drug delivery system can be used in many different pharmaceutical agents.Type: ApplicationFiled: January 16, 2009Publication date: March 17, 2011Applicants: Shenyang Pharmaceutical University, Hangzhou Yuhong Pharmaceutical Science & Technology Co., Ltd.Inventors: Yihui Deng, Xiaohui Dong, Li Shi, Yi Lu
-
Publication number: 20110059020Abstract: To provide a liposome composition, which contains at least one liposome; gas entrapped in the liposome, and at least one metal oxide particle encapsulated in or adsorbed on the liposome, wherein the liposome composition satisfies a ratio B/A of 0.01 to 5, where A is a volume of the gas contained in the liposome on the basis of micro liter, and B is a mass of the at least one metal oxide particle contained in the liposome on the basis of milligram.Type: ApplicationFiled: September 7, 2010Publication date: March 10, 2011Applicants: FUJIFILM Corporation, FUKUOKA UNIVERSITYInventors: Hiroyuki HIRAI, Katsuro Tachibana
-
Publication number: 20110059159Abstract: Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of use.Type: ApplicationFiled: January 30, 2009Publication date: March 10, 2011Applicant: THE ROCKEFELLER UNIVERSITYInventors: Thomas P. Sakmar, Thomas Huber, Sourabh Banerjee
-
Publication number: 20110052676Abstract: Disclosed herein is a composition for delaying cellular senescence comprising from about 0.01 wt % to about 5 wt % of Hexapeptide-11(Phe-Val-Ala-Pro-Phe-Pro), based on the total weight of the composition, and a dermatologically-acceptable carrier for the peptide selected from the group consisting of water, oil, alcohol, silicone, and combinations thereof.Type: ApplicationFiled: August 30, 2010Publication date: March 3, 2011Inventor: James Vincent Gruber